Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval Corsicana Daily Sun
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval Voice of Alexandria
Sunshine Biopharma's 2mg Tablet for Endometriosis Pain Wins Canadian Approval Stock Titan
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval Benzinga
Recurrent hemorrhagic pleural effusion presents as a challenge for both the clinician and the patient, with common causes being tuberculosis, malignancy, and collagen vascular diseases. Among uncommon causes of recurrent …
To apply an MR-PheWAS to infer causality between NSW and multiple health outcomes.
EMs is a chronic, estrogen-dependent systemic inflammatory disorder defined by the ectopic implantation of endometrial glands and stroma and is frequently associated with dysmenorrhea, chronic pelvic pain, infertility, and substantial …
Endometriosis is a common gynecological disorder characterized by the growth of endometrial-like tissue outside the uterine cavity, leading to chronic inflammation, pelvic pain, and infertility. Reliable mouse models are essential …
Woman refused to see a male gynecologist. Then one appointment changed her mind The Mary Sue
Dysmenorrhoea is one of the most frequent manifestations of chronic pelvic pain. Endometriosis and adenomyosis are among the most common pathological causes of secondary dysmenorrhoea. Symptoms often persist despite treatment, …